Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 13;16(1):2.
doi: 10.1186/s13024-021-00424-9.

New approaches to symptomatic treatments for Alzheimer's disease

Jeffrey Cummings  1
Affiliations
Review

New approaches to symptomatic treatments for Alzheimer's disease

Jeffrey Cummings. Mol Neurodegener. .

Erratum in

Abstract

Background: Successful development of agents that improve cognition and behavior in Alzheimer's disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder.

Discussion: There have been no recent approvals of cognitive enhancing agents for AD. There are currently 6 cognitive enhancers in Phase 2 trials and 4 in phase 3. They represent a variety of novel mechanisms. There has been progress in developing new treatments for neuropsychiatric symptoms in AD with advances in treatment of insomnia, psychosis, apathy, and agitation in AD. There are currently 4 AD-related psychotropic agents in Phase 2 trials and 7 in Phase 3 trials. Many novel mechanisms are being explored for the treatment of cognitive and behavioral targets. Progress in trial designs, outcomes measures, and population definitions are improving trial conduct for symptomatic treatment of AD.

Conclusions: Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.

Keywords: Agitation; Alzheimer’s disease; Apathy; Clinical trials; Cognition; Depression; Drug development; Neuropsychiatry; Psychosis.

PubMed Disclaimer

Conflict of interest statement

JC has provided consultation to Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in ADAMAS, AnnovisBio, MedAvante, BiOasis. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory.

Figures

Fig. 1
Fig. 1
Number of cognitive enhancing agents for Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [, –28]
Fig. 2
Fig. 2
Number of agents addressing neuropsychiatric symptoms of Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [, –28]
See this image and copyright information in PMC

References

    1. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. Nat Rev Dis Primers. 2015;1:150. - PubMed
    1. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease. Lancet. 2016;388(10043):505–517. doi: 10.1016/S0140-6736(15)01124-1. - DOI - PubMed
    1. Francis PT, Ramirez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology. 2010;59(4–5):221–229. doi: 10.1016/j.neuropharm.2010.02.010. - DOI - PubMed
    1. Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019;103(2):263–293. doi: 10.1016/j.mcna.2018.10.009. - DOI - PubMed
    1. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimer Dement TRCI. 2020;20(6):e12050. - PMC - PubMed

Publication types